D-dimer In Patients With atRial Fibrillation rEceiving antiCoagulation Therapy

Wuhan Asia Heart Hospital1,194 enrolled

Overview

This is a sigle-center, prospective study to evaluate the role of D-Dimer testing in patients with atrial fibrillation receiving Dabigatran or warfarin anticoagulation therapy.

Patients with atrial fibrillation receiving Dabigatran or warfarin anticoagulation therapy was screened and signed to two group: Dabigatran group and Warfarin group. D-dimer test was analyzed before and 3 months after anticoagulation starting specificly. Patients were followed-up for at least 12 months,and clinical outcomes, including thrombotic events major bleeding events and all-cause deaths were recorded during follow-up period.

Study Type

OBSERVATIONAL

Enrollment

1,194

Conditions

Atrial Fibrillation Strokes Thrombotic

Interventions

Dabigatran Etexilate 110mgDRUG

Dabigatran Etexilate 110mg, BID

Warfarin SodiumDRUG

Target INR:1.6-3.0

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Non-valvular atrial fibrillation * Receiving oral anticoagulation therapy and have good compliance Exclusion Criteria: * Life expectancy less than 1 year * Thrombosis or major bleeding history within 3 months * Refusal to Participate

Locations (1)

WAHH

Wuhan, Hubei, China

Outcomes

Primary Outcomes

Cardiovascular events

Thrombotic events, cardiovascular deaths, major bleeding events

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.